CBO

Newly Launched Andreas & Thomas Struengmann Award Recognizing Outstanding DACH Life Science Entrepreneurs Announces 2024 Finalists

Retrieved on: 
вторник, мая 28, 2024
Science, Cardiology, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Listeria monocytogenes non-coding RNA, Partnership, Patient, Biomedical Research, DISCO, CBO, DACH, News, RNA, Deutsches Museum, Translation, Award, Ecosystem, Therapy, Roman, Drug development, BioNTech, Incubator, Cancer, Spacecraft, Growth, Genome, CSO, Medicine, BMS, Future, Pharmaceutical industry

The committee of the newly initiated Andreas & Thomas Struengmann Award today announced the finalist selection for the inaugural 2024 award.

Key Points: 
  • The committee of the newly initiated Andreas & Thomas Struengmann Award today announced the finalist selection for the inaugural 2024 award.
  • It is the first of its kind in the DACH region and aims to recognize impressive entrepreneurial talents and achievements in the life science arena.
  • In addition, they highlight that the DACH life science ecosystem is thriving and represents an internationally recognized hub for excellence and creativity.” said Andreas and Thomas Struengmann.
  • To learn more about the award and stay up to date on the latest news visit our newly launched website: www.struengmannaward.de .

Secarna Pharmaceuticals and Orbit Discovery Enter Collaboration to Discover and Develop Peptide-conjugated Targeted Antisense Oligonucleotide Therapeutics

Retrieved on: 
вторник, мая 28, 2024
Health, Stem Cells, Research, Pharmaceutical, Science, Biotechnology, Patient, CBO, Discovery, Toxicity, Medication, Orbit, Drug discovery, Cell, Library, Therapy, Peptide, N-Acetylgalactosamine, Antibody, Fine chemical

Secarna Pharmaceuticals GmbH & Co. KG (Secarna), a leading independent European antisense drug discovery and development company, and Orbit Discovery Ltd. (Orbit), a leader in the discovery of therapeutic peptide hits, today announced that they have entered into a collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics.

Key Points: 
  • Secarna Pharmaceuticals GmbH & Co. KG (Secarna), a leading independent European antisense drug discovery and development company, and Orbit Discovery Ltd. (Orbit), a leader in the discovery of therapeutic peptide hits, today announced that they have entered into a collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics.
  • The addition of cyclic peptides to Secarna’s proprietary ASO discovery and development platform will expand its therapeutic spectrum, positioning it to develop targeted antisense assets beyond modalities such as antibodies and sugar molecules, like GalNAc.
  • “We are very pleased to embark on this collaboration with Orbit Discovery, as the team’s expertise in peptide discovery and development will further enhance our capabilities for the development of targeted antisense therapeutics”, said Konstantin Petropoulos, CBO of Secarna Pharmaceuticals.
  • The collaboration not only strengthens Secarna's ability to create targeted antisense therapeutics, paired to cyclic peptides, but will also extend the reach of antisense approaches, potentially offering new treatment options for a wider range of diseases.

Vedomi-Hydrogen and GreenEarthX to Revolutionize Offtake Market for Green Hydrogen and Derivatives, Accelerating Global Decarbonization Efforts

Retrieved on: 
вторник, мая 14, 2024
Hydrogen, Partnership, Green hydrogen, CBO, Risk, GEX, Memorandum of understanding, Methanol, World Future Energy Summit, SAF, CPO, Cryptocurrency

This collaboration promises to deliver comprehensive Off-take, Spot and Forwards Contracts trading opportunities, enabling stakeholders to effectively manage their long-term energy requirements on a tokenized marketplace.

Key Points: 
  • This collaboration promises to deliver comprehensive Off-take, Spot and Forwards Contracts trading opportunities, enabling stakeholders to effectively manage their long-term energy requirements on a tokenized marketplace.
  • "We are witnessing a significant uptake of our offering from stakeholders across the value chain, underscoring the urgent need for swift global decarbonization," remarked Christian Benigni, Founder and CEO of Vedomi-Hydrogen.
  • This collaboration between Vedomi-Hydrogen and GreenEarthX marks a significant milestone in the global transition towards sustainable energy solutions.
  • By revolutionizing the offtake market for green hydrogen, both companies are paving the way for a cleaner, greener future.

ZOOZ Power Announces CEO Transition

Retrieved on: 
среда, мая 15, 2024
EV, CBO, Cortica, MX1, Marketing, Lucent, KLA, Growth, Non-governmental organization, Interim, Acquisition, RR Media, Knowledge, ECI Telecom, Management

Lod, Israel, May 15, 2024 (GLOBE NEWSWIRE) -- ZOOZ Power Ltd. (NASDAQ and TASE: ZOOZ), a leading provider of flywheel-based power boosting solutions for the EV charging infrastructure market, today announced that subject to shareholder approval, Avi Cohen, Executive Chairman, will assume the role of Interim CEO, succeeding Boaz Weizer, who will step down effective June 1, 2024.

Key Points: 
  • Lod, Israel, May 15, 2024 (GLOBE NEWSWIRE) -- ZOOZ Power Ltd. (NASDAQ and TASE: ZOOZ), a leading provider of flywheel-based power boosting solutions for the EV charging infrastructure market, today announced that subject to shareholder approval, Avi Cohen, Executive Chairman, will assume the role of Interim CEO, succeeding Boaz Weizer, who will step down effective June 1, 2024.
  • ZOOZ has initiated a thorough search process to identify its next CEO to lead the company into the next phase of its growth.
  • Avi Cohen will serve as Interim CEO until a new CEO is appointed.
  • Commenting on the transition, Avi Cohen stated, “I would like to express my gratitude to Boaz Weizer for his contribution to ZOOZ Power.

Pragma Bio Strengthens Strategic Leadership with Addition of Esteemed Advisors and an Independent Board Member

Retrieved on: 
среда, мая 22, 2024
Health, Technology, Software, Clinical Trials, Artificial Intelligence, Pharmaceutical, Biotechnology, TYK2, Patient, Doctor of Philosophy, Takeda, CBO, J&J, Therapy, GSK, Growth, Cancer, Drug discovery, Medicine, Acquisition, Knowledge, AstraZeneca, Multimedia, Pharmacyclics

The new additions include Stuart Chaffee, PhD , as Independent Board Member, and Raquel Izumi, PhD , and Abbas Kazimi, M.S.

Key Points: 
  • The new additions include Stuart Chaffee, PhD , as Independent Board Member, and Raquel Izumi, PhD , and Abbas Kazimi, M.S.
  • (Graphic: Business Wire)
    Stuart Chaffee, PhD, brings nearly three decades of experience in the biotechnology and biopharma industry to Pragma Bio's board.
  • "I am honored to join Pragma Bio's board at such an exciting time in the company's journey," remarked Chaffee.
  • With these strategic additions, Pragma Bio reaffirms its commitment to innovation and excellence in biotechnology.

Alloy Therapeutics Announces Platform License Agreement with Lilly

Retrieved on: 
вторник, мая 21, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Health Technology, Genetics, Patient, CBO, Eli Lilly and Company, Immunoglobulin G, Therapy, Ecosystem, Drug discovery, Lilly, ATX, Antibody, Pharmaceutical industry

Alloy Therapeutics, a biotechnology ecosystem company dedicated to democratizing access to biologics drug discovery platforms and services, announced today a licensing agreement for its murine platforms for fully human antibody discovery with Eli Lilly and Company.

Key Points: 
  • Alloy Therapeutics, a biotechnology ecosystem company dedicated to democratizing access to biologics drug discovery platforms and services, announced today a licensing agreement for its murine platforms for fully human antibody discovery with Eli Lilly and Company.
  • The non-exclusive license provides Lilly access to the ATX-Gx™ and ATX-CLC™ mouse platforms and broad rights to use the Alloy platforms for antibody drug discovery and development under this multi-year collaboration.
  • Launched in 2019, the Alloy ATX-Gx platform has rapidly become the industry standard fully human transgenic mouse platform to enable therapeutic discovery programs utilized by over 170 partners.
  • In 2023 Alloy launched the ATX-CLC platform expressing common light chain antibodies with full heavy chain diversity to enable efficient, modular bispecific discovery.

GRAMINEX®, L.L.C. Final Publication of a Peer Reviewed Clinical Trial with Graminex® Flower Pollen Extract Focusing on Women’s Urinary Incontinence in Current Urology.

Retrieved on: 
понедельник, мая 13, 2024
Health, Consumer, Women, General Health, Clinical Trials, Pharmaceutical, Vitamins, Supplements, RCT, Urology, Woman, L.L.C, Urinary incontinence, Karger Publishers, CBO, Trial of the century, Menopause

is pleased to announce publication of a peer reviewed clinical study with Graminex® Flower Pollen Extract for women’s urinary incontinence and urinary health in Current Urology.

Key Points: 
  • is pleased to announce publication of a peer reviewed clinical study with Graminex® Flower Pollen Extract for women’s urinary incontinence and urinary health in Current Urology.
  • The study was conducted as a randomized, double-blind, placebo-controlled study to investigate the effectiveness of Graminex® Flower Pollen Extracts in 114 healthy women with urinary incontinence.
  • A full version is available at: Current Urology - Original Article
    “Many women experience urinary incontinence throughout their lives during postpartum, menopause, and the natural aging process.
  • There is limited natural support to help improve the symptoms of urinary incontinence currently on the market.

Skyborne Technologies Unveils the Cerberus Modular Integration

Retrieved on: 
четверг, мая 9, 2024
Cerberus, AITR, System, IP, CBRNE, United States Army, CMI, MILSPEC, BDA, EW, UAS, Electronics, Robotics, Fort Moore, Rain, Artificial intelligence, CBO, Telescopic sight

BRISBANE, Australia, May 10, 2024 (GLOBE NEWSWIRE) -- Skyborne Technologies is proud to unveil Cerberus Modular Integration (MI), a multi-mission, man-packable, Group 2 sUAS equipped with modular kinetic and non-kinetic payloads.

Key Points: 
  • The old Cerberus GLH lacked the endurance, survivability and accuracy required for a real operation.
  • Adrian Dudok, CBO and co-founder, Skyborne Technologies, says, “Our customers asked for a multi-mission modular payload lethal small UAS capable of delivering organic low cost strike capability with the ability to perform non-kinetic sensors and effectors operations.
  • We’re proud to release the Cerberus MI to deliver a unique capability to our customers and the warfighter.
  • The new Cerberus MI will be landing in the hands of customers from Q4 this year.”
    Skyborne Technologies Pty Ltd, is an Australian defence technology company developing smart aerial robotics, with its flagship tri-tilt rotor lethal sUAS, Cerberus UAS.

ALX Oncology Appoints Allison Dillon as Chief Business Officer

Retrieved on: 
вторник, мая 7, 2024
University, Cancer, CD47, Campbell Alliance, Investment, GU, Commercial, Hematology, Marketing, Trial of the century, Medulloblastoma, Bevacizumab, Growth, Roche, Consultant, Senior, Science, Patient, Acquisition, Lead, CBO, Howard Hughes Medical Institute, SAN

SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the appointment of Allison Dillon, Ph.D., as Chief Business Officer (“CBO”).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the appointment of Allison Dillon, Ph.D., as Chief Business Officer (“CBO”).
  • “We are excited to welcome Allison to our leadership team in the midst of this promising growth period for our Company,” said Jason Lettmann, Chief Executive Officer of ALX Oncology.
  • “For over 15 years, Allison has worked to develop and deliver novel oncology products to patients with cancer.
  • “With near-term clinical trial readouts and a strong balance sheet, ALX Oncology is well positioned for greater success.

Panax Offers AI-powered Cash Flow Management Platform, Secures $15M to Scale and Meet Rapidly Growing Global Demand

Retrieved on: 
среда, мая 8, 2024
Security, Data Management, Technology, Finance, Fintech, Banking, Business, Apps, Applications, Accounting, Professional Services, Venture Capital, Artificial Intelligence, Digital Cash Management, Digital Assets, Other Technology, Payments, Software, Mastercard, CFO, Niv, Capital, ERP, Traction, Forecasting, Rest, Panax, Automation, Noam Mills, PES, Multimedia, CBO, Growth, Gartner, Oddity

Amid high-interest rates and cash uncertainty, finance teams are struggling to proactively manage complex cash flow, liquidity and financial risks.

Key Points: 
  • Amid high-interest rates and cash uncertainty, finance teams are struggling to proactively manage complex cash flow, liquidity and financial risks.
  • Panax offers an AI-driven cash flow management platform that empowers mid-market and large companies with complex treasury management needs to gain control and sustainability and optimize liquidity.
  • View the full release here: https://www.businesswire.com/news/home/20240508668284/en/
    Panax Offers AI-powered Cash Flow Management Platform, Secures $15M to Scale and Meet Rapidly Growing Global Demand (Photo: Business Wire)
    Finance teams are challenged with managing numerous bank accounts, fintech solutions, locations, currencies and entities.
  • Panax's customers report saving $100K+ a year on interest payments through enhanced cash control, while others experience a 15-20% increase in cash invested in interest-bearing accounts.